LANDMARK BIO

POSTmark™ AAV

Our Platform Optimized for Scale-up and Transfer (POSTmark™) consists of mirrored R&D and cGMP equipment, and process to enable:

- Support for all stages of development from R&D to cGMP scale
- cGMP AAV in 6-9 months
- Research grade AAV representative of cGMP AAV
- Reduce time, costs and risks

POSTmark™ was developed so that your first shot, is your best shot

POSTmark™ AAV At-a-Glance

- cGMP AAV in 6-9 months
- Support for all stages of development from Benchtop R&D to cGMP scale
- Mirrored process/analytical development & cGMP unit operations supports IND-enabling materials
- Optimized for 3 plasmid transient transfection
- In-house QC & fill/finish
- Customizable process & analytical development packages including potency assay development
- In-house CMC Regulatory expertise and support including supporting health authority interactions, briefing books and module writing
- Our cGMP facilities, laboratories and processes have been developed and implemented to meet US FDA cGMP regulatory requirements including 21 CFR Parts 11, 210, 211, 610, and 1271; relevant US FDA Guidelines; and relevant ICH Quality Guidelines

R&D SUPPLY — 4 - 8 WEEKS

GMP AAV — 6 - 9 MONTHS

LANDMARK BIO: 300 NORTH BEACON STREET, WATERTOWN, MA 02472
INFO@LANDMARKBIO.COM | WEBSITE: WWW.LANDMARKBIO.COM

LANDMARK BIO MANUFACTURING BREAKTHROUGHS

POSTmark™ AAV Platform

UPSTREAM

Expansion → Transfection → Lysis/Clarification

Cell Viability



Population Doubling Level



DOWNSTREAM

Chromatography → Concentration & Formulation → Fill/Finish

Physical Titers



Recovery



About Landmark Bio

Landmark Bio is a collective endeavor that brings together academia, industry, and hospitals to advance the development of transformative medicines. Founding members include Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc.

Landmark Bio provides end-to-end and process development, biomanufacturing capabilities and consulting services for life sciences innovators working on novel modalities such as cell, gene, and RNA medicines, and develop innovative manufacturing technologies to enable the advancement of novel therapies.

LANDMARK BIO: 300 NORTH BEACON STREET, WATERTOWN, MA 02472
INFO@LANDMARKBIO.COM | WEBSITE: WWW.LANDMARKBIO.COM

LANDMARK BIO
MANUFACTURING BREAKTHROUGHS